Tyligand Bioscience (泰励生物) Pre-IPO: Late Entrant to the KRAS G12D Target
China biotech Tyligand Bioscience aims to raise $100 million through Hong Kong listing with CITIC as sole sponsor. We look at its late-stage core...
436 Views
Pre-IPO Suzhou Ribo Life Science (PHIP Updates) - Some Points Worth the Attention
Ribo's IPO pricing (HK$57.97/share) is reasonable and leaves room for valuation increases, thus there is good upside on IPO debut, which is in line...
289 Views
HSCI Index Rebalance Preview and Stock Connect (Mar 2026): Many Changes Following Huge IPO Quarter
There could be 74 changes for the HSCI in March. That could result in 64 changes to the Southbound Stock Connect list and also have implications...
1.5k Views
Primer: GenFleet Therapeutics (GENFL12 HK) - Sep 2025
GenFleet Therapeutics is a clinical-stage biopharmaceutical company with a strong focus on developing novel therapies in oncology and...
106 Views
Pre-IPO GenFleet Therapeutics (PHIP Updates) - Some Points Worth the Attention
GenFleet's IPO debut is eye-catching.Besides continuous enthusiasm for Biotech IPO, the endorsement of famous cornerstone investors brings great...
845 Views